Dr. Lal PathLabs Limited

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, LALPATHLAB.NS has a market cap of 235.2B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while LALPATHLAB.NS trades at ₹1,416.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas LALPATHLAB.NS's P/E ratio is 44.50. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to LALPATHLAB.NS's ROE of +0.24%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to LALPATHLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check LALPATHLAB.NS's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, SAILIFE.NS has a market cap of 217.1B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while SAILIFE.NS trades at ₹1,067.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas SAILIFE.NS's P/E ratio is 64.75. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to SAILIFE.NS's ROE of +0.15%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to SAILIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check SAILIFE.NS's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, VIJAYA.NS has a market cap of 109.5B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while VIJAYA.NS trades at ₹1,112.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas VIJAYA.NS's P/E ratio is 68.70. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to VIJAYA.NS's ROE of +0.20%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to VIJAYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check VIJAYA.NS's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, VIJAYA.BO has a market cap of 109.4B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while VIJAYA.BO trades at ₹1,110.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas VIJAYA.BO's P/E ratio is 68.96. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to VIJAYA.BO's ROE of +0.20%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to VIJAYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check VIJAYA.BO's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, METROPOLIS.NS has a market cap of 96.8B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while METROPOLIS.NS trades at ₹476.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas METROPOLIS.NS's P/E ratio is 57.67. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to METROPOLIS.NS's ROE of +0.13%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to METROPOLIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check METROPOLIS.NS's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, METROPOLIS.BO has a market cap of 96.8B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while METROPOLIS.BO trades at ₹477.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas METROPOLIS.BO's P/E ratio is 57.87. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to METROPOLIS.BO's ROE of +0.13%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to METROPOLIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check METROPOLIS.BO's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, THYROCARE.NS has a market cap of 21B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while THYROCARE.NS trades at ₹412.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas THYROCARE.NS's P/E ratio is 45.31. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to THYROCARE.NS's ROE of +0.26%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to THYROCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check THYROCARE.NS's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, THYROCARE.BO has a market cap of 21B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while THYROCARE.BO trades at ₹412.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas THYROCARE.BO's P/E ratio is 45.47. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to THYROCARE.BO's ROE of +0.26%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to THYROCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check THYROCARE.BO's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, VIMTALABS.NS has a market cap of 20.4B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while VIMTALABS.NS trades at ₹462.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas VIMTALABS.NS's P/E ratio is 27.52. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to VIMTALABS.NS's ROE of +0.20%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to VIMTALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check VIMTALABS.NS's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, VIMTALABS.BO has a market cap of 20.4B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while VIMTALABS.BO trades at ₹461.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas VIMTALABS.BO's P/E ratio is 27.53. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to VIMTALABS.BO's ROE of +0.20%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to VIMTALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check VIMTALABS.BO's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, KRSNAA.BO has a market cap of 19.5B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while KRSNAA.BO trades at ₹600.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas KRSNAA.BO's P/E ratio is 24.62. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to KRSNAA.BO's ROE of +0.09%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to KRSNAA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check KRSNAA.BO's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, KRSNAA.NS has a market cap of 19.5B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while KRSNAA.NS trades at ₹600.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas KRSNAA.NS's P/E ratio is 24.56. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to KRSNAA.NS's ROE of +0.09%. Regarding short-term risk, LALPATHLAB.BO is more volatile compared to KRSNAA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check KRSNAA.NS's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, SURAKSHA.BO has a market cap of 14.7B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while SURAKSHA.BO trades at ₹284.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas SURAKSHA.BO's P/E ratio is 45.15. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to SURAKSHA.BO's ROE of +0.16%. Regarding short-term risk, LALPATHLAB.BO is less volatile compared to SURAKSHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check SURAKSHA.BO's competition here

LALPATHLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LALPATHLAB.BO stands at 235.2B. In comparison, SURAKSHA.NS has a market cap of 14.7B. Regarding current trading prices, LALPATHLAB.BO is priced at ₹1,415.30, while SURAKSHA.NS trades at ₹285.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LALPATHLAB.BO currently has a P/E ratio of 44.54, whereas SURAKSHA.NS's P/E ratio is 45.27. In terms of profitability, LALPATHLAB.BO's ROE is +0.24%, compared to SURAKSHA.NS's ROE of +0.16%. Regarding short-term risk, LALPATHLAB.BO is more volatile compared to SURAKSHA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LALPATHLAB.BO.Check SURAKSHA.NS's competition here